Enhanced Prognostic Assessment of Glioblastoma Multiforme Using Machine Learning: Integrating Multimodal Imaging and Treatment Features: A review

ROHIT CHOUDHARY[1], PRIYABRATA THATOI[2], SUSHREE SWAPNIL ROUT[3]
[1]*University of Texas, Dallas*
[2]*Oklahoma State University*
[3]*Dr. L.H. Hiranandani Hospital, India*

Abstract- Glioblastoma multiforme (GBM) is the primary and most malignant form of brain tumor with an unexceptionally low prognosis and a highly variable genome. The cancer's multifactorial nature and variable response to the stated therapy preclude the use of standard prognostic factors. We can improve prognosis and the individual therapeutic management plan by utilizing the domain of multimodal imagining and a new approach in machine learning. Here, the author wonders how the different modes of the image, such as MRI, PET, and CT, the therapeutic characteristics incorporated with the features linked to therapy, and the ML models can give a system check of GBM. The integrated data of anatomy, metabolism, and clinical picture enhances the accuracy of prognosis and facilitates the selection of further treatment methods for the patient. This paper examines various factors such as current techniques and approaches, the advantages of utilizing data in diverse ways, and how machine learning handles all types of data. The increased accuracy reveals facts that contribute to the model's clinical relevance, indicating a better prognosis and subsequent better treatment. The paper looks at the issue regarding handling model heterogeneity and interpretability. Future work in this field will deal with finer tuning of the learning algorithms, data communication protocols, and new real-time monitoring instruments. Therefore, integrating MMC and MTT with features and ML is valuable in improving the prognosis and treatment of GBM to optimize patients' results.

Indexed Terms- Glioblastoma Multiforme (GBM), Multimodal Imaging, Machine Learning, Prognostication, Magnetic Resonance Imaging, Clinical Implications.

I. INTRODUCTION

Glioblastoma multiforme (GBM) turns out to be one of the most aggressive, most immature primary brain tumor types, with high proliferation rates and resistance to conventional therapy. However, at present, GBM remains one of the most life-threatening primary brain tumor entities, with a median survival duration ranging from 12 to 15 months, even with the use of new types of treatment. Scientists characterize GBM as a genetic and cellular tumor, observing its heterogeneity at multiple disease stages. Therefore, clinicians are usually confused or have a poor idea of the likely patient outcomes. In this regard, evaluating the prognosis is critical in response to the interventions and patients' expectations.

We have used several of the more traditional prediction paradigms for GBM, such as age, performance status, or tumor grade. Such approaches must be more specific due to the disorder. Consequently, incorporating other more contemporary techniques and the data accrued from therapy has the prospect of improving the estimate of the survival probabilities. Besides structural imaging, including MRI and CT images, we also have functional imaging with PET and molecular imaging, which gives information on tumor morphological appearance, metabolic activity, and molecular features. These imaging features, when combined with data gathered from therapeutic interventions, will provide more comprehensive information on the tumor's nature and treatment response.

Machine learning, as one of the subdivisions of artificial intelligence, has opened up a new perspective on dealing with medical data. Big data, for example, enables not only the identification of traditional patterns and correlations through traditional statistical tools, but also the definition of unpredictable patterns and correlations by a machine learning algorithm. We have also developed machine learning models using GBM, which depict patients' potential outcomes based on data extracted from imaging, clinical, and treatment responses. These improvements are significant because they incorporate imaging and therapy features into these models, resulting in more precise and accurate prognosis assessments [16].

As a result, this review article will specifically focus on the current literature on multimodal imaging and therapy feature fusion and its integration into machine learning-based predictive models for GBM. The strategies that underline this integrated approach are reviewing the literature and capturing knowledge from formally published works. This paper will critically review the findings of the study to show the advantages of this approach, the likely challenges that any organization is bound to encounter when implementing the solution, and the possible recommendations for future studies. Thus, in its totality, the work contributes to an understanding of a spectrum of opportunities to apply the current innovations in prognostic assessment and the overall treatment of GBM patients to improve their condition.

II. OVERVIEW OF MULTIMODAL IMAGING IN GBM

Combining two or more imaging techniques to analyze the data has greatly improved the GBM diagnosis and subsequent therapeutic management strategies. Artifacts with intrinsic characteristics can be classified as having high value. Traditionally, we regard GBM as heterogeneous, making it challenging to define the tumor's extent, nature, and response to treatment. Conventional imaging studies typically only depict the anatomical or functional trait of the tumor, providing minimal information about the lesion. However, new changes in imaging techniques, particularly multimodal imaging, which combines several imaging methods to form a new process, provide a new way of approaching the GBM, allowing for more information about the tumor [25].

MRI is the most used imaging modality in the management of GBM, and most clinicians like it due to its accuracy in diagnosis. For the representation of the location and extent of the tumor concerning the brain tissues, the modality provides excellent image contrast of the soft tissues and high spatial resolution. We use T1 and T2 weighted MRI sequences to provide detailed structural information. In comparison, the study uses DWI and PWI to elucidate the function of the body part. Therefore, we can use DWI to determine the density of the tumor cells. At the same time, by entering the tumor, PWI provides information on blood flow within the tumor that can help to define its malignancy and probable reaction to a treatment [26].

Since PET provides metabolic information on the tumor, MRI frequently pairs with PET. PET scans use substances like 18F-fluorodeoxyglucose (FDG), which labels the cancerous cells' metabolism rate. The glucose metabolic rate in GBM cells is high, as depicted by this PET. We can also attempt to define the active tumor areas not visible on MRI. It is advantageous to differentiate between tumor progression after treatment and treatment side effects, such as radiation encephalopathy. We are making new PET tracers that are very good at finding molecular features connected to GBM, like amino acid transport or hypoxia. This will give us even more biomolecular information about how the tumor works [3].

Another modality is computed tomography (CT), which can also be helpful. However, doctors typically do not use it for a detailed evaluation of GBM patients. The emergency ward employs CT due to its speed and availability, which provides valuable information in cases of acutely worsening neurological status [6]. When contemplating a biopsy or resection, it aids in surgical planning by providing visualization of bones and calcification. Still, CT is inferior to MRI in terms of soft tissue contrast and, therefore, is inferior in depicting tumor characteristics [21].

Table 1: Overview of Multimodal Imaging Techniques in GBM

Imaging Modality	Primary Use	Advantages	Limitations
MRI (Magnetic Resonance Imaging)	Anatomical imaging, assessing tumor size and location	High spatial resolution, functional imaging options (e.g., DWI, PWI)	May not capture metabolic activity

PET (Positron Emission Tomography)	Metabolic and molecular imaging	Highlights regions of high glucose uptake, useful for identifying active tumor areas	Lower spatial resolution, high cost
CT (Computed Tomography)	Rapid imaging, surgical planning	Good for bone imaging, quick scanning	Less detailed soft tissue contrast compared to MRI
fMRI (Functional MRI)	Brain activity mapping, identifying functional areas	Non-invasive, maps brain activity	Requires patient cooperation, indirect measure of neural activity
DTI (Diffusion Tensor Imaging)	Assessing white matter tracts	Identifies disruption in white matter	Sensitive to motion artifacts

III. MACHINE LEARNING IN GBM PROGNOSTICATION

Machine Learning is now unfolding itself as a versatile technique in the sphere of cancer that can help in prognostication and management of extensive diseases like GBM. GBM is an inherently diverse and invasive cancer for which conventional predictive techniques that depend on clinical predictors and basic statistical models are highly problematic [9]. As I have argued, this new approach – using big data sets with machine learning algorithms – is much more effective in predicting individual patient outcomes and is the ultimate goal of clinical management.

Unpacking the term significantly is feeding data meant to recognize patterns and make some decisions or generate predictions based on a new data set. These large-scale and complex data from various sources such as imaging, genomic, clinical, and therapeutic are generally used to build the ML models for GBM. This way, the models learn from various data sets and spot connections and correlations that might be overlooked. This capability is handy in GBM prognosis, where the model requires multiple data types to balance the heterogeneity of the tumor and patients.

In GBM, one of the significant areas of interest of ML is the analysis of imaging data, often combining different techniques such as MRI and PET. Conventional image review is meager and interpreted by radiologists by experience and judgment, which makes it more diverse. On the other hand, imaging data can be analyzed in terms of patterns and features about clinical outcomes by machine learning algorithms with more accuracy and lesser variability. For instance, lesions' structures, sizes, shapes, and textural characteristics can be computed using the ML models and related to the patient's survival rates or treatment outcomes. These models offer more precise and individualized prognostic estimates.

Clinical and molecular data and imaging are also included in ML models to determine the prognosis of GBM. For instance, the patient's age, performance status, and tissue biomarkers like the mutational status of the isocitrate dehydrogenase IDH 1 and the methylation status of the O6-methylguanine methyltransferase MGMT gene are included. Such broad data allow the building of so-called versatile models implying several factors related to the given disease to reach higher prognostic quality.

Different ML approaches have been used in GBM research, with various merits and demerits associated with each. Neural Networks, Support Vector Machines (SVM), and Random Forests are typically



Fig 1: Workflow of integrating multimodal imaging and machine learning GBM prognostication

incorporated classifiers. Random Forests, for instance, boast of the following: they can work with big datasets with numerous features; they are immune to overfitting. SVMs are mainly applied to classification problems, including subtypes of tumors. Neural Networks, particularly Deep Learning Models, have emerged to be the most promising in handling big data and higher dimensional data, including images and genomic sequences [4].

However, the use of ML in GBM prognostication has challenges, as discussed below. One of the major concerns is that the models require a large number of high-quality data for training to be effective [12]. Since GBM is a rare disease, inadequate data is frequently present, which complicates model building and can also threaten external validity. In the same regard, reliance on opaque algorithms, such as deep learning networks, is an issue of interpretation and clinical credibility.

IV. INTEGRATION OF MULTIMODAL IMAGING AND THERAPY FEATURES

The combination of multimodal imaging and therapy features is a significant innovation in the GBM and the approach to achieving a higher level of personalized treatment. This method leverages the capabilities of different imaging techniques and the specific details of therapeutic information in developing a better picture of the tumor's behavior and the response to treatment to put together a better picture of the patient's prognosis. Due to the massive complexity and interindividual variability of GBM, such an integrative approach may serve as a blueprint for more sound and personalized risk assessments.

Multimodal imaging additionally uses various sorts of imaging, giving distinctive data concerning the tumor. For instance, magnetic resonance imaging (MRI) offers detailed anatomical images and functional imaging, such as diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI). The advanced MRI methods described above provide information about the tumor's relative cellularity, vascularity, and overall architecture, crucial considerations in determining tumor grade and prognosis, and the possible effectiveness of the treatment being considered. Positron Emission Tomography (PET) provides metabolic and molecular images that provide increased glucose uptake or regions of low oxygen in a tumor, indicating regions of high tumor metabolic activity or resistance to treatments [13]. Computed Tomography (CT) provides additional value. It involves rapid imaging and is useful in surgical planning. Combining information from all of these approaches can provide clinicians with a superior understanding of the tumor over space and time, as well as its metabolic activity and interactions with the surrounding structures in the brain.

Similarly to imaging, therapeutic factors, including the extent of surgical resection, prescribed radiation dose, and chemotherapy regimens, are the cornerstone of therapy and contribute to the creation of the patient's outcome. Thus, proxies such as the degree of surgical resection are known to directly affect survival, with more extensive resection indicating more prolonged survival. Nonetheless, the planning of surgery, which is whether it will be possible and safe to resect various tumor areas, can be significantly informed by imaging data. Likewise, radiation therapy and chemotherapy responses depend on the biological properties of the tumor, which are estimable based on imaging features [11]. For example, abiding the PWI perfusion decrease to a particular area of cancer may refer to hypoxic regions, which are less susceptible to radiation therapy treatment; thus, the plans to target resistant regions are modified.

Multimodal imaging and therapy planning results in better patient outcomes as this model slowly builds up accurate prospective models. This is where machine learning (ML) comes into play because it can assess the amount and complexity of data and make connections between entities that may be unnoticed during the usual analysis of such data. By obtaining imaging and therapy features as inputs, ML models can give a comprehensive view of the state of the tumor and the way it will behave in the course of the treatment [8]. For example, an example model could involve MRI volume parameters, PET markers metabolic rate, and tumor resection extent to predict mortality rates and recurrence or progression. These models can be enhanced when molecular markers, such as mutation profile or protein expression, are added to them, resulting in a multi-dimensional model incorporating tumor and patient characteristics.

The present study revealed more advantages to integrating multimodal imaging and therapy features than in prognostic prediction alone. This strategy enhances patient care since the treatment plan depends on the patient and their disease. For instance, if the image of the patient in question shows high metabolic rates on PET and low regional blood flow on MRI, the individual will be classified into a category of a candidate for specific or intensive treatment. On the other hand, patients with a lower risk profile indicated by the integration might require a less stringent treatment plan, reducing the adverse effects but not the effectiveness of the treatment.



Fig 2: Feature importance graph showing relative importance of various features in predicting outcomes GBM patients.

V. MACHINE LEARNING MODELS UTILIZING INTEGRATED DATA

Multimodal imaging and therapy features-based machine learning models for prognostic and therapeutic purposes in Glioblastoma Multiforme (GBM) patients are at a new level of development. These models build on the volume of information supplied from multiple varieties of data, thereby improving the understanding of the disease and the identification of special aspects relating to the particular patient concerned. Heterogeneous clinical imaging data, clinical variables, and therapy response data can all be used to build models that give very individualized prognostic estimates and therapeutic management.

Machine learning models are first created by gathering and preparing data from different sources. In the context of GBM, this often entails obtaining MRI, PET, and CT scan images and some clinical data about the patient, including demographics, genetic information, and history of treatments [10]. Additional clinical data include therapy data, including the degree of resection, radiation dose prescriptions and distributions, and chemotherapy regimens. The preprocessing step is crucial because it can determine the data quality one will feed to a given model. This could include position scaling of image data, dealing with missing values in the patient record database, and harmonizing different data sets.

The decoding step is the final part of the preparation stage, where data is ready for analysis so that machine learning algorithms can be developed to build relations and identify patterns within an integrated database. It is now seen that the choice of algorithm depends on the characteristics of the data on hand and the purpose of the survey. The usual algorithms adopted in GBM research include random forests, SVM, and neural networks. For instance, Random Forests can work well with big datasets and many variables, determining which characteristics significantly impact prediction [17]. SVMs are generally used for classification tasks, such as discrimination between two or more subtypes of cancer or between various categories of treatment outcomes. Neural networks, intense learning, can model and analyse complex and high-dimensional data, such as imaging sequences, and be able to pick out factors that more superficial forms of the model may not easily discern.

Such models are usually checked as cross-validated or, if more confident, externally validated. Cross-validation implies partitioning the data into training and testing datasets in several ways to avoid having the model perform best on any of the partition methods. External validation, however, ventures on an entirely different data set that is not used in the model development process, making the results more reliable. The effectiveness of these models is assessed based on means like accuracy, sensitivity, specificity, and AUC–ROC. There are differences between 'good models' and 'high-performing models'; good models are high-performing, high-performing models are stable and high-performing, and true high-performing models are stable and consistently accurate in different data settings for patient outcomes.

First, using multimodal imaging and therapy features in machine learning models has certain benefits. Because these models use more data types, the picture of GBM they can provide will be much more detailed than that given by, for instance, only sentiment Analysis models. For example, neurological-affective disorders could be best evaluated by using MRI and PET scans alongside clinical data about the patient's reaction to prior treatment. This leads to the discovery of patients who may benefit from specific therapies or may be at higher risk for relapse, hence the possibility of localized intercessions [1].

But, the establishment of these integrated models is challenging. Of all the sources of potential bias that may compromise the credibility of the results obtained from empirical research, two stand out: Firstly, the data are heterogeneous in terms of their origin and quality. Some of the observational data, for example, may differ depending on the used protocols, the equipment, and the operators, which introduces discrepancies that may influence the model performance. Further, using large and complex datasets involves high computational power and a professional approach to data analysis, which may only sometimes be possible in different research or clinical centres. Model interpretability is also an issue because complex models such as those in deep learning networks are often termed 'black boxes', and therefore, clinicians cannot easily understand how the model has made a particular prediction [2].

VI. CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

Combining multimodal imaging and therapy features with the machine learning models will have giant clinical implications for managing Glioblastoma Multiforme (GBM). This has been postulated to increase the precision in prognosis, tailor therapy modalities, and, therefore, the quality of outcomes. These models integrate multiple data types, such as imaging, clinical measurements, and therapy response, to yield a complete picture of the tumor behavior and its interaction with the administered intervention, thereby enabling more precise treatment strategies.

Among all the expectations of an integrated approach, one of the primary and significant areas is the possibility of a more accurate prognosis. Conventional approaches to predictive assessment can be based on a few clinical characteristics and do not consider tumor heterogeneity. This way, the machine learning models, based on the integrated multimodal data, can identify these intricate and hidden relationships, which allows for defining a more accurate prognosis of patients' outcomes, including indicators such as survival rates or risk of tumor relapse. For example, an increased understanding of patient-specific risk that attends MRI and PET scans of tumor volume and metabolic activity and therapeutic management can refine decision-making about management and follow-on care [24].

Moreover, introducing therapy features in these models increases the possibility of individualizing clients' treatment. The treatment in GBM is usually a combination of surgery, radiation, and chemotherapy; their efficacy, however, will depend on the tumor profile and the general health status of the patient [15].

Models that take responses to prior therapies and other imaging data into consideration can assist in determining the therapy plan that best suits the specific patient. This can enhance the extent to which specific treatment will be useful for the patient's problem or situation and reduce side effects that might be so severe as to compromise the patient's quality of life and or shorten the patient's lifespan.

Another area of further development is the use of additional technologies and data penetration. For instance, combining genomics and molecular principles into the machine learning model could provide even more information about the tumor's bioactivity and how it can be treated. Further, real-time data from wearables or patient monitoring might give a more real-time view into the effectiveness of treatments and disease progress, which might add to the personalization.

CONCLUSION

Thus, the proposed approach is consequent and, to the best of our knowledge, a novel for managing Glioblastoma Multiforme (GBM) with the help of multimodal imaging and therapy features and machine learning algorithms. As the models incorporated the data from MRI, PET, therapy, and other sources, they provided richer information about the general polyphonic nature of GBM. The above-enhanced synchronization enhances the performance of forecasts concerning the patients' outcomes and the overall treatment process.

These linked datasets assist in creating machine learning algorithms that can distinguish between multiple relations and dependence, which standard methodologies fail to see; therefore, they offer superior treatment. For example, through imaging data over the characteristics of the tumor and the corresponding therapeutic response, these models ensure the clinician provides the patient with the best therapy required given the nature of the cancer while at the same time reducing the toxic effects that come with the treatment. An individual patient approach not only meets the requirements for proper patient handling but also a longer survival duration and a better quality of life can be expected in patients with GBM.

In the future, more sharpening of the introduced ML algorithms, in addition to the constant increase in the extent of use of new technologies and types of data, will increase the saturation of the predictive models and the treatment planning. The development of systematic approaches for data collection and integration of RT-monitoring data will probably enhance the applicability and effectiveness of these models in clinical practice. Once research proceeds, these will help increment the management of GBM, strengthening the hope of the patients and doctors.

REFERENCES

[1] Abla, O., & Janka, G. (2017). Histiocytic Disorders. Springer. Retrieved from http://books.google.ie/books?id=LFI_DwAAQBAJ&printsec=frontcover&dq=neurological-affective+disorders+could+be+best+evaluated+by+using+MRI+and+PET+scans+alongside+clinical+data+about+the+patient%27s+reaction+to+prior+treatment.+This+leads+to+the+discovery+of+patients+who+may+benefit+from+specific+therapies+or+may+be+at+higher+risk+for+relapse,+hence+the+possibility+of+localized+intercessions&hl=&cd=1&source=gbs_api

[2] Afshar, P., Mohammadi, A., Plataniotis, K. N., Oikonomou, A., & Benali, H. (2019). From Handcrafted to Deep-Learning-Based Cancer Radiomics: Challenges and Opportunities. IEEE Signal Processing Magazine, 36(4), 132–160. https://doi.org/10.1109/msp.2019.2900993

[3] Alexiou, G., Tsiouris, S., Goussia, A., Kyritsis, A., Voulgaris, S., Fotopoulos, A., . . . Kretzschmar, H. (2010). Abstracts from the 9th Meeting of The European Association of NeuroOncology, September 16-19, 2010, Maastricht, The Netherlands. Neuro-Oncology, 12(Supplement 3), iii1–iii66. https://doi.org/10.1093/neuonc/noq085

[4] Author, S., & Javanmard, S. (2024). Revolutionizing Medical Practice: The Impact of Artificial Intelligence (AI) on Healthcare. Open Access Journal of Applied Science and Technology, 2(1), 01–16. https://doi.org/10.33140/oajast.02.01.07

[5] CARS 2023—Computer Assisted Radiology and Surgery Proceedings of the 37th International Congress and Exhibition Munich, Germany, June 20–23, 2023. (2023). International Journal of Computer Assisted Radiology and Surgery, 18(S1), 1–123. https://doi.org/10.1007/s11548-023-02878-2

[6] Chan, A. W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., . . . Moher, D. (2013). SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, 346(jan08 15), e7586. https://doi.org/10.1136/bmj.e7586

[7] Chang, K., Bai, H. X., Zhou, H., Su, C., Bi, W. L., Agbodza, E., & Wen, P. Y. (2020). Residual convolutional neural network for determining IDH status in low- and high-grade gliomas from MR imaging. Clinical Cancer Research, 24(5), 1073-1081.

[8] Fantini, S., Sassaroli, A., Tgavalekos, K. T., & Kornbluth, J. (2016). Cerebral blood flow and autoregulation: current measurement techniques and prospects for noninvasive optical methods. Neurophotonics, 3(3), 031411. https://doi.org/10.1117/1.nph.3.3.031411

[9] Goldsmith, Z. (2022, January 26). The Tumor Microenvironment Regulates Retinoblastoma

Cell Survival. https://doi.org/10.21007/etd.cghs.2018.0472

[10] Grossmann, N. (2018, March 6). Defining the biological and clinical basis of radiomics. https://doi.org/10.26481/dis.20180308pg

[11] Hanin, L. (2011). Why Victory in the War on Cancer Remains Elusive: Biomedical Hypotheses and Mathematical Models. Cancers, 3(1), 340–367. https://doi.org/10.3390/cancers3010340

[12] Karri, R., Chen, Y. P. P., & Drummond, K. J. (2022). Using machine learning to predict health-related quality of life outcomes in patients with low grade glioma, meningioma

[13] , and acoustic neuroma. PLoS ONE, 17(5), e0267931. https://doi.org/10.1371/journal.pone.0267931

[14] Klement, R. J., & Kämmerer, U. (2011). Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutrition & Metabolism, 8(1), 75. https://doi.org/10.1186/1743-7075-8-75

[15] Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., ... & Ellison, D. W. (2016). The 2016 World Health Organization classification of central nervous system tumors: a summary. Acta Neuropathologica, 131(6), 803-820.

[16] Maschio, M. (2012). Brain Tumor-Related Epilepsy. Current Neuropharmacology, 10(2), 124–133. https://doi.org/10.2174/157015912800604470

[17] Mohy-Ud-Din, H., & Rathore, S. (2020). Radiomics and Radiogenomics in Neuro-oncology. Springer Nature. Retrieved from http://books.google.ie/books?id=3KDSDwAAQBAJ&printsec=frontcover&dq=Using+GBM,+machine+learning+models+for+predicting+the+outcomes+of+patients+based+on+imaging+and+clinical+data,+as+well+as+treatment+response+data,+have+been+built.+Including+multimodal+imaging+and+therapy+features+in+such+models+is+a+significant+improvement+because+it+will+allow+for+tailored+and+more+accurate+prognosis+assessments.&hl=&cd=4&source=gbs_api

[18] Nisar, D. E. M., Amin, R., Shah, N. U. H., Ghamdi, M. a. A., Almotiri, S. H., & Alruily, M. (2021). Healthcare Techniques Through Deep Learning: Issues, Challenges and Opportunities. IEEE Access, 9, 98523–98541. https://doi.org/10.1109/access.2021.3095312

[19] Oermann, E. K., Collins, B. T., Erickson, K., Suy, S., Desai, S., Yu, X., ... & Gupta, V. (2014). CyberKnife, enhanced by tumor metabolism imaging, improves outcomes in patients with malignant glioma. Frontiers in Oncology, 4, 241.

[20] Rathore, S., Akbari, H., Rozycki, M., Abdullah, K. G., Nasrallah, M., Binder, Z. A., ... & Davatzikos, C. (2018). Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning—Journal of Medical Imaging, 5(2), 021203.

[21] Scientific poster session. (2008). Neuroradiology, 50(S1), 79–131. https://doi.org/10.1007/s00234-008-0439-x

[22] Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., . . . Vullierme, M. P. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 105(3), 212–244. https://doi.org/10.1159/000471879

[23] Tiwari, P., Viswanath, S., Lee, G., Madabhushi, A., & Rosen, M. (2016). Multimodal data integration for predicting recurrence of ovarian cancer. Medical Image Analysis, pp. 34, 177-189.

[24] Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., ... & Hayes, D. N. (2010). Integrated genomic analysis identifies clinically relevant glioblastoma subtypes characterized by PDGFRA, IDH1, EGFR, and NF1 abnormalities. Cancer Cell, 17(1), 98-110.

[25] Zanoni, L., Nanni, C., Fanti, S., Behe, M., Römer, W., Tempesta, D., . . . Caobelli, F. (2018). Prostate cancer imaging and therapy. https://doi.org/10.52717/gpjl7081

[26] Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019). Machine learning for integrating data in biology and medicine: Principles, practice, and opportunities. Information Fusion, 50, 71–91. https://doi.org/10.1016/j.inffus.2018.09.012

[27] Zoccatelli, G., Alessandrini, F., Beltramello, A., & Talacchi, A. (2013). Advanced magnetic resonance imaging techniques in brain tumours surgical planning. Journal of Biomedical

Science and Engineering, 06(03), 403–417. https://doi.org/10.4236/jbise.2013.63a